Teva Pharmaceutical Industries Ltd. (TEVA) said third-quarter profit will miss estimates even as it left the full-year forecast unchanged, leaving analysts wondering where the generic-drug maker will find more than $1 billion in added revenue in the fourth quarter. Third-quarter earnings excluding some costs will be $1.22 a share, Chief Financial Officer Eyal Desheh said on a conference call yesterday. That falls short of the $1.35 a share analysts expected, based on the average of 20 estimates compiled by Bloomberg. Yet Petach Tikva, Israel-based Teva said it still expects to meet a full-year target of $4.90 to $5.20 a share.
